Hippie Flip: Difference between revisions
From BurnZero
mNo edit summary |
mNo edit summary |
||
| Line 1: | Line 1: | ||
'''Co-use of 3,4-Methylenedioxy methamphetamine ([[MDMA]]) with [[psilocybin]] / [[magic mushrooms]] is termed '' | '''Co-use of 3,4-Methylenedioxy methamphetamine ([[MDMA]]) with [[psilocybin]] / [[magic mushrooms]] is termed ''hippie flipping''.''' It is thought that by combining MDMA with psilocybin this may reduce [[Adverse Psychedelic Effects|challenging experiences]] and enhances positive experiences associated with the medicine. Some evidence points <ref>'''Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences'''. Richard J. Zeifman, Hannes Kettner, Broc A. Pagni, Austin Mallard, Daniel E. Roberts, David Erritzoe, Stephen Ross & Robin L. Carhart-Harris. Published: 22 August 2023. Accessed on 27th October 2023 via: https://www.nature.com/articles/s41598-023-40856-5#Sec2:~:text=Primary%20analyses-,Challenging%20experiences,high%20dose%20MDMA%20use%2C%20t(672)%E2%80%89%3D%E2%80%89%20%E2%88%92%E2%80%890.68%2C%20p%E2%80%89%3D%E2%80%890.498.,-Examining%20group%20differences</ref>to the use of low dose MDMA (50–75 mg) with psilocybin associates with significantly lower levels of total challenging experience. | ||
'''References''' | '''References''' | ||
Revision as of 06:37, 7 January 2024
Co-use of 3,4-Methylenedioxy methamphetamine (MDMA) with psilocybin / magic mushrooms is termed hippie flipping. It is thought that by combining MDMA with psilocybin this may reduce challenging experiences and enhances positive experiences associated with the medicine. Some evidence points [1]to the use of low dose MDMA (50–75 mg) with psilocybin associates with significantly lower levels of total challenging experience.
References
- ↑ Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences. Richard J. Zeifman, Hannes Kettner, Broc A. Pagni, Austin Mallard, Daniel E. Roberts, David Erritzoe, Stephen Ross & Robin L. Carhart-Harris. Published: 22 August 2023. Accessed on 27th October 2023 via: https://www.nature.com/articles/s41598-023-40856-5#Sec2:~:text=Primary%20analyses-,Challenging%20experiences,high%20dose%20MDMA%20use%2C%20t(672)%E2%80%89%3D%E2%80%89%20%E2%88%92%E2%80%890.68%2C%20p%E2%80%89%3D%E2%80%890.498.,-Examining%20group%20differences